Bristol Myers Squibb Reveals Key Outcomes from KRYSTAL-12 Study on KRAZATI (adagrasib) Demonstrating Main Goal of Halting Disease Progress in Advanced KRASG12C-Altered Non-Small Cell Lung Cancer.

The EU Commission has approved the use of Merck's drug KEYTRUDA® (pembrolizumab) in combination with chemotherapy as a first treatment.

Encouraging initial human trial Phase 1B results for VRON-0200, an innovative checkpoint modifier for Chronic Hepatitis B, were showcased as a late-breaking entry at the APASL 2024 Global Liver Conference.

Drug monitoring, in the context of healthcare and pharmacology, refers to the process of tracking and evaluating the use, safety, efficacy, and overall impact of medications in clinical practice.

Biond Biologics reveals at the 2024 AACR Annual Meeting, the introduction of their pioneering anti-ILT3 antibody, BND-35, designed to transform the tumor microenvironment.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung condition causing scarring and stiffness, which makes breathing harder over time.

REGENXBIO Reveals Study in The Lancet on Initial Trial for Single-Dose Gene Therapy ABBV-RGX-314 Targeting Wet Age-Related Macular Degeneration.

Targeted therapy is a type of cancer treatment that uses drugs or other substances to specifically attack cancer cells without harming normal cells as much as possible.

Neurocrine Biosciences Launches Early-Stage Trial for New VMAT2 Blocker, NBI-1065890, in Adult Participants.

Advancing GPCR-Targeted Therapy: Tectonic Therapeutics' GEODe Platform Overcomes Discovery Challenges.

Gilead and Xilio have entered into a unique licensing deal dedicated to the development of an oncology-targeted IL-12 initiative.

A drug delivery system is a method or technology used to transport a pharmaceutical compound into the body to achieve a therapeutic effect.